CTNNB1 and non-small cell lung carcinoma: In our EGFRM+ NSCLC cohort we detected cases that prior to erlotinib treatment showed concomitant pathogenic mutations of the CTNNB1 gene coding for β-catenin, the main effector in the Wnt/β-catenin signaling pathway that transactivates cell proliferation-related genes [51,176].